- Home
- THFF vs FHTX Comparison
THFF vs FHTX Comparison
Compare THFF & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- FHTX
- Stock Information
- Founded
- THFF 1984
- FHTX 2015
- Country
- THFF United States
- FHTX United States
- Employees
- THFF N/A
- FHTX N/A
- Industry
- THFF Major Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- THFF Finance
- FHTX Health Care
- Exchange
- THFF Nasdaq
- FHTX Nasdaq
- Market Cap
- THFF 589.0M
- FHTX 513.7M
- IPO Year
- THFF N/A
- FHTX 2020
- Fundamental
- Price
- THFF $48.92
- FHTX $7.72
- Analyst Decision
- THFF Hold
- FHTX Strong Buy
- Analyst Count
- THFF 1
- FHTX 5
- Target Price
- THFF $45.00
- FHTX $16.00
- AVG Volume (30 Days)
- THFF 68.3K
- FHTX 131.6K
- Earning Date
- THFF 10-22-2024
- FHTX 11-04-2024
- Dividend Yield
- THFF 3.68%
- FHTX N/A
- EPS Growth
- THFF N/A
- FHTX N/A
- EPS
- THFF 3.68
- FHTX N/A
- Revenue
- THFF $190,119,000.00
- FHTX $25,515,000.00
- Revenue This Year
- THFF N/A
- FHTX N/A
- Revenue Next Year
- THFF $12.01
- FHTX $8.77
- P/E Ratio
- THFF $13.30
- FHTX N/A
- Revenue Growth
- THFF N/A
- FHTX N/A
- 52 Week Low
- THFF $34.58
- FHTX $2.70
- 52 Week High
- THFF $50.63
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- THFF 62.21
- FHTX 42.02
- Support Level
- THFF $47.37
- FHTX $7.33
- Resistance Level
- THFF $50.25
- FHTX $9.33
- Average True Range (ATR)
- THFF 1.32
- FHTX 0.72
- MACD
- THFF 0.02
- FHTX -0.13
- Stochastic Oscillator
- THFF 79.76
- FHTX 16.46
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services, and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.